| Followers | 24 |
| Posts | 2163 |
| Boards Moderated | 1 |
| Alias Born | 10/29/2006 |
Sunday, March 25, 2007 10:40:20 PM
TRMS - Chart
Trimeris Inc
Float: 15.56M
Most recent analyst opinion: 16-Mar-07 First Albany Downgrade Buy to Neutral
Company Overview
Trimeris, Inc. (Trimeris) is a biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the human immunodeficiency virus (HIV), the Company's first commercial product and its compounds under research offer a novel mechanism of action with the potential to treat a variety of medically important viral diseases. Fuzeon is the Company's first-generation HIV fusion inhibitor, developed in collaboration with F. Hoffmann-La Roche Ltd (Roche). Fuzeon is a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41.
Trimeris Inc
Float: 15.56M
Most recent analyst opinion: 16-Mar-07 First Albany Downgrade Buy to Neutral
Company Overview
Trimeris, Inc. (Trimeris) is a biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the human immunodeficiency virus (HIV), the Company's first commercial product and its compounds under research offer a novel mechanism of action with the potential to treat a variety of medically important viral diseases. Fuzeon is the Company's first-generation HIV fusion inhibitor, developed in collaboration with F. Hoffmann-La Roche Ltd (Roche). Fuzeon is a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
